Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
40 hedge funds and large institutions have $32.1M invested in Lumos Pharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 6 closing their positions.
2% less funds holding
Funds holding: 41 → 40 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
17% less capital invested
Capital invested by funds: $38.8M → $32.1M (-$6.73M)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.78M |
| 2 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$557K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$555K |
| 4 |
State Street
Boston,
Massachusetts
|
+$125K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$99.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.78M |
| 2 |
Renaissance Technologies
New York
|
-$297K |
| 3 |
Two Sigma Investments
New York
|
-$123K |
| 4 |
BlackRock
New York
|
-$105K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$41.1K |
LUMO Hedge Fund Activity: Q2 2021 in Review
40 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2021, worth a combined $32.1M — down 17% from $38.8M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LUMO and 5 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 5 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $1.78M. The largest seller was Deerfield Management, cutting an estimated $3.78M.
- 40 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2021, down from 41 in Q1 2021.
- Funds reported $32.1M of Lumos Pharma, Inc. Common Stock stock for Q2 2021, down 17% quarter-over-quarter.
- 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2021 and 6 closed out, a net change of -1 holder.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2021 was T. Rowe Price Associates, an estimated $1.78M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2021 was Deerfield Management, an estimated $3.78M sold.
Based on aggregated 13F filings for Q2 2021.